Kenvue Inc.

Under a comprehensive downside stress test, Kenvue experiences a simultaneous contraction across channel demand, product pricing, and capital structure. If the primary retail customer (12% of revenue) cuts inventory order volumes by 15% and demands 300 bps of incremental promotional allowances, annual revenue declines by over $270M and operating margin compresses from 15.96% down toward 13.0%. Concurrently, private label penetration across US retail ($6,460M US sales) erodes volumes in Skin Health ($4,114M) and Essential Health ($4,632M). On the balance sheet, refinancing $2,750M of upcoming debt maturities at yields exceeding the pre-tax cost of debt of 6.06% increases annual interest expense by $40M to $60M, reducing net cash flow available for dividends ($1,581M paid in FY2025). In this scenario, equity value re-rates to the bear-case floor of $13.49, representing a 21.6% decline from the analysis price of $17.20.

Narrow

Kenvue commands a narrow economic moat underpinned by durable intangible brand assets and entrenched retail distribution networks across consumer health. As the former consumer healthcare division of Johnson & Johnson, Kenvue holds premier global brand leadership across Self Care ($6,378M net sales in FY2025), Essential Health ($4,632M), and Skin Health and Beauty ($4,114M). These essential healthcare categories benefit from inelastic consumer demand, high household replenishment frequency, and strong physician and healthcare professional recommendations that insulate market share from cyclical economic downturns.

The company's distribution scale provides significant shelf-space advantages across multinational mass-market and pharmacy channels. In FY2025, Kenvue generated $15,124M in consolidated revenue, supported by substantial geographic diversification spanning North America ($7,259M), EMEA ($3,721M), Asia Pacific ($2,775M), and Latin America ($1,369M). While a single key customer accounts for 12% of total net sales, this stable channel alignment reflects high retail foot-traffic reliance on Kenvue's category-leading brands, preserving retail shelf dominance even as private label products expand.

However, the moat remains narrow rather than wide due to intense competition from large-scale consumer packaged goods peers such as Colgate-Palmolive (operating margin of 20.97%) and Procter & Gamble (operating margin of 22.09%), as well as growing private-label alternatives in skin health and personal hygiene. Furthermore, mass merchant buyer power constrains pricing realization and necessitates ongoing promotional allowances, bounding operating margin expansion at 16.0% to 17.0% relative to peer median profitability.

Kenvue Inc. (KVUE) trades at 14.7x forward earnings against a peer median of 20.1x. Its EV/EBITDA of 11.6x compares with a peer median of 14.7x. The comparison uses 4 peers: The Estee Lauder Companies Inc., Colgate-Palmolive Company, The Procter & Gamble Company and Kimberly-Clark Corporation, as of 2026-10-04.

Maintain existing equity holdings in Kenvue Inc. at the report-date price of $17.20. The stock trades at a modest 5.3% discount to our central Fair value of $18.17, offering 5.6% upside alongside a solid dividend yield. Inelastic demand across core Self Care brands ($6,378M revenue) supports operating cash generation of $2,197M, but elevated leverage ($8,524M debt) and channel concentration (12% top customer) warrant a balanced posture.^4,7

Investors should collect the regular dividend while observing management's execution on post-separation supply chain efficiencies and upcoming debt refinancing. We recommend holding the position and reassessing if operational margin expansion accelerates toward high-performing peer benchmarks or if retailer destocking pressures materialize.